Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2025)

Aclaris Therapeutics has reported FCF Margin over the past 9 years, most recently at 1008.88% for Q4 2025.

  • Quarterly results put FCF Margin at 1008.88% for Q4 2025, down 91184.0% from a year ago — trailing twelve months through Dec 2025 was 602.27% (down 49440.0% YoY), and the annual figure for FY2025 was 602.27%, down 49439.0%.
  • FCF Margin for Q4 2025 was 1008.88% at Aclaris Therapeutics, down from 332.07% in the prior quarter.
  • Over the last five years, FCF Margin for ACRS hit a ceiling of 506.21% in Q3 2024 and a floor of 1454.44% in Q1 2022.
  • Median FCF Margin over the past 5 years was 656.8% (2021), compared with a mean of 620.0%.
  • Biggest five-year swings in FCF Margin: skyrocketed 89660bps in 2022 and later crashed -91184bps in 2025.
  • Aclaris Therapeutics' FCF Margin stood at 1150.9% in 2021, then surged by 78bps to 254.3% in 2022, then skyrocketed by 83bps to 43.79% in 2023, then tumbled by -122bps to 97.04% in 2024, then tumbled by -940bps to 1008.88% in 2025.
  • The last three reported values for FCF Margin were 1008.88% (Q4 2025), 332.07% (Q3 2025), and 563.53% (Q2 2025) per Business Quant data.